Matthew C. Baker
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Zanubrutinib in Patients With IgG4-Related Disease (NCT04602598) | Matthew C. Baker | 2022-08-01 |
| BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome (NCT04563195) | Matthew C. Baker | 2022-02-01 |
Track Matthew C. Baker automatically
Every clearance here is in the API, with alerts when new ones post.